Cargando…

The Feasibility of Percutaneous Dilatational Tracheostomy in Immunosuppressed ICU Patients with or without Thrombocytopenia

BACKGROUND: Percutaneous dilatational tracheostomy (PDT) has become the preferred method in several intensive care units (ICUs), but data on PDT performed in immunosuppressed and thrombocytopenic patients are scarce. This study aimed to analyze the feasibility of PDT in immunosuppressed and thromboc...

Descripción completa

Detalles Bibliográficos
Autores principales: Angelberger, Marianne, Barnikel, Michaela, Fraccaroli, Alessia, Tischer, Johanna, Antón, Sofía, Pawlikowski, Alexandra, op den Winkel, Mark, Stemmler, Hans Joachim, Stecher, Stephanie-Susanne
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Hindawi 2022
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9134848/
https://www.ncbi.nlm.nih.gov/pubmed/35646396
http://dx.doi.org/10.1155/2022/5356413
_version_ 1784713840942907392
author Angelberger, Marianne
Barnikel, Michaela
Fraccaroli, Alessia
Tischer, Johanna
Antón, Sofía
Pawlikowski, Alexandra
op den Winkel, Mark
Stemmler, Hans Joachim
Stecher, Stephanie-Susanne
author_facet Angelberger, Marianne
Barnikel, Michaela
Fraccaroli, Alessia
Tischer, Johanna
Antón, Sofía
Pawlikowski, Alexandra
op den Winkel, Mark
Stemmler, Hans Joachim
Stecher, Stephanie-Susanne
author_sort Angelberger, Marianne
collection PubMed
description BACKGROUND: Percutaneous dilatational tracheostomy (PDT) has become the preferred method in several intensive care units (ICUs), but data on PDT performed in immunosuppressed and thrombocytopenic patients are scarce. This study aimed to analyze the feasibility of PDT in immunosuppressed and thrombocytopenic patients compared to conventional open surgical tracheostomy (OST). METHODS: We retrospectively analyzed the charts of patients who underwent PDT or OST between May 2017 and November 2020. Our outcomes were stoma site infections and bleeding complications. RESULTS: 63 patients underwent PDT, and 21 patients underwent OST. Distribution of gender ratio, age, SAPS II, time of ventilation before tracheostomy, and preexisting hematooncological diseases was comparable between the two groups. After allogeneic stem cell transplantation (alloSCT), patients were more likely to undergo PDT than OST (p=0.033). The PDT cohort suffered from mucositis more frequently (p=0.043). There were no significant differences in leucocyte or platelet count on the tracheostomy day. Patients with coagulation disorders and patients under immunosuppression were distributed equally among both groups. Stoma site infection was documented in five cases in PDT and eight cases in the OST group. Moderate infections were remarkably increased in the OST group. Smears were positive in six cases in the PDT group; none of these patients had local infection signs. In the OST group, smears were positive in four cases; all had signs of a stroma site infection. Postprocedural bleedings occurred in eight cases (9.5%) and were observed significantly more often in the OST group (p=0.001), leading to emergency surgery in one case of the OST group. CONCLUSION: PDT is a feasible and safe procedure in a predominantly immunosuppressed and thrombocytopenic patient cohort without an increased risk for stoma site infections or bleeding complications.
format Online
Article
Text
id pubmed-9134848
institution National Center for Biotechnology Information
language English
publishDate 2022
publisher Hindawi
record_format MEDLINE/PubMed
spelling pubmed-91348482022-05-27 The Feasibility of Percutaneous Dilatational Tracheostomy in Immunosuppressed ICU Patients with or without Thrombocytopenia Angelberger, Marianne Barnikel, Michaela Fraccaroli, Alessia Tischer, Johanna Antón, Sofía Pawlikowski, Alexandra op den Winkel, Mark Stemmler, Hans Joachim Stecher, Stephanie-Susanne Crit Care Res Pract Research Article BACKGROUND: Percutaneous dilatational tracheostomy (PDT) has become the preferred method in several intensive care units (ICUs), but data on PDT performed in immunosuppressed and thrombocytopenic patients are scarce. This study aimed to analyze the feasibility of PDT in immunosuppressed and thrombocytopenic patients compared to conventional open surgical tracheostomy (OST). METHODS: We retrospectively analyzed the charts of patients who underwent PDT or OST between May 2017 and November 2020. Our outcomes were stoma site infections and bleeding complications. RESULTS: 63 patients underwent PDT, and 21 patients underwent OST. Distribution of gender ratio, age, SAPS II, time of ventilation before tracheostomy, and preexisting hematooncological diseases was comparable between the two groups. After allogeneic stem cell transplantation (alloSCT), patients were more likely to undergo PDT than OST (p=0.033). The PDT cohort suffered from mucositis more frequently (p=0.043). There were no significant differences in leucocyte or platelet count on the tracheostomy day. Patients with coagulation disorders and patients under immunosuppression were distributed equally among both groups. Stoma site infection was documented in five cases in PDT and eight cases in the OST group. Moderate infections were remarkably increased in the OST group. Smears were positive in six cases in the PDT group; none of these patients had local infection signs. In the OST group, smears were positive in four cases; all had signs of a stroma site infection. Postprocedural bleedings occurred in eight cases (9.5%) and were observed significantly more often in the OST group (p=0.001), leading to emergency surgery in one case of the OST group. CONCLUSION: PDT is a feasible and safe procedure in a predominantly immunosuppressed and thrombocytopenic patient cohort without an increased risk for stoma site infections or bleeding complications. Hindawi 2022-05-26 /pmc/articles/PMC9134848/ /pubmed/35646396 http://dx.doi.org/10.1155/2022/5356413 Text en Copyright © 2022 Marianne Angelberger et al. https://creativecommons.org/licenses/by/4.0/This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.
spellingShingle Research Article
Angelberger, Marianne
Barnikel, Michaela
Fraccaroli, Alessia
Tischer, Johanna
Antón, Sofía
Pawlikowski, Alexandra
op den Winkel, Mark
Stemmler, Hans Joachim
Stecher, Stephanie-Susanne
The Feasibility of Percutaneous Dilatational Tracheostomy in Immunosuppressed ICU Patients with or without Thrombocytopenia
title The Feasibility of Percutaneous Dilatational Tracheostomy in Immunosuppressed ICU Patients with or without Thrombocytopenia
title_full The Feasibility of Percutaneous Dilatational Tracheostomy in Immunosuppressed ICU Patients with or without Thrombocytopenia
title_fullStr The Feasibility of Percutaneous Dilatational Tracheostomy in Immunosuppressed ICU Patients with or without Thrombocytopenia
title_full_unstemmed The Feasibility of Percutaneous Dilatational Tracheostomy in Immunosuppressed ICU Patients with or without Thrombocytopenia
title_short The Feasibility of Percutaneous Dilatational Tracheostomy in Immunosuppressed ICU Patients with or without Thrombocytopenia
title_sort feasibility of percutaneous dilatational tracheostomy in immunosuppressed icu patients with or without thrombocytopenia
topic Research Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9134848/
https://www.ncbi.nlm.nih.gov/pubmed/35646396
http://dx.doi.org/10.1155/2022/5356413
work_keys_str_mv AT angelbergermarianne thefeasibilityofpercutaneousdilatationaltracheostomyinimmunosuppressedicupatientswithorwithoutthrombocytopenia
AT barnikelmichaela thefeasibilityofpercutaneousdilatationaltracheostomyinimmunosuppressedicupatientswithorwithoutthrombocytopenia
AT fraccarolialessia thefeasibilityofpercutaneousdilatationaltracheostomyinimmunosuppressedicupatientswithorwithoutthrombocytopenia
AT tischerjohanna thefeasibilityofpercutaneousdilatationaltracheostomyinimmunosuppressedicupatientswithorwithoutthrombocytopenia
AT antonsofia thefeasibilityofpercutaneousdilatationaltracheostomyinimmunosuppressedicupatientswithorwithoutthrombocytopenia
AT pawlikowskialexandra thefeasibilityofpercutaneousdilatationaltracheostomyinimmunosuppressedicupatientswithorwithoutthrombocytopenia
AT opdenwinkelmark thefeasibilityofpercutaneousdilatationaltracheostomyinimmunosuppressedicupatientswithorwithoutthrombocytopenia
AT stemmlerhansjoachim thefeasibilityofpercutaneousdilatationaltracheostomyinimmunosuppressedicupatientswithorwithoutthrombocytopenia
AT stecherstephaniesusanne thefeasibilityofpercutaneousdilatationaltracheostomyinimmunosuppressedicupatientswithorwithoutthrombocytopenia
AT angelbergermarianne feasibilityofpercutaneousdilatationaltracheostomyinimmunosuppressedicupatientswithorwithoutthrombocytopenia
AT barnikelmichaela feasibilityofpercutaneousdilatationaltracheostomyinimmunosuppressedicupatientswithorwithoutthrombocytopenia
AT fraccarolialessia feasibilityofpercutaneousdilatationaltracheostomyinimmunosuppressedicupatientswithorwithoutthrombocytopenia
AT tischerjohanna feasibilityofpercutaneousdilatationaltracheostomyinimmunosuppressedicupatientswithorwithoutthrombocytopenia
AT antonsofia feasibilityofpercutaneousdilatationaltracheostomyinimmunosuppressedicupatientswithorwithoutthrombocytopenia
AT pawlikowskialexandra feasibilityofpercutaneousdilatationaltracheostomyinimmunosuppressedicupatientswithorwithoutthrombocytopenia
AT opdenwinkelmark feasibilityofpercutaneousdilatationaltracheostomyinimmunosuppressedicupatientswithorwithoutthrombocytopenia
AT stemmlerhansjoachim feasibilityofpercutaneousdilatationaltracheostomyinimmunosuppressedicupatientswithorwithoutthrombocytopenia
AT stecherstephaniesusanne feasibilityofpercutaneousdilatationaltracheostomyinimmunosuppressedicupatientswithorwithoutthrombocytopenia